Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex

Plasma didanosine concentration data from 36 patients receiving once-a-day therapy and from 33 patients receiving twice-a-day therapy were subject to population pharmacokinetic analysis with the computer program NONMEM. Once- or twice-a-day regimens of didanosine were administered intravenously (i.v.) (dose: 0.8-33 mg/kg) during the first 2 weeks of therapy, and orally (dose: 1.6-66 mg/kg) for the remaining 4 weeks of therapy. Plasma pharmacokinetics were determined after the first and last (steady-state) i.v. and oral doses. Population pharmacokinetic parameters for the combined i.v. and oral steady-state data were (mean [%CV]): systemic clearance, CL, 0.70 (5.2) L/h/kg; central compartment volume, Vc, 0.18 (32) L/kg; steady-state distribution volume, Vdss, 0.84 (6.8) L/kg; first-order absorption rate constant, Ka, 1.3 (9.5) hr-1; and bioavailable fraction, F, 0.34 (8.5). Interindividual variability (omega) was (%CV) 22.3 and 71.0 for CL and Vc, respectively. Intraindividual (residual) variability (sigma) in plasma concentrations (%CV) was 50.2. Body weight, sex, and age did not account for the variability in either CL or Vc, and the use of alternate pharmacokinetic models did not reduce the value of intraindividual variability. Population parameters for the combined i.v. and oral first-dose data were generally similar to those for the steady-state data. The parameters can be used to design dosing regimens in patients using the Bayesian feedback approach.

This article has been cited by other articles:

				E. I Ette and P. J Williams Population Pharmacokinetics II: Estimation Methods Ann. Pharmacother., November 1, 2004; 38(11): 1907 - 1915. [Abstract] [Full Text] [PDF]

				K. H. P. Moore, G. J. Yuen, E. K. Hussey, G. E. Pakes, J. J. Eron Jr., and J. A. Bartlett Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials Antimicrob. Agents Chemother., December 1, 1999; 43(12): 3025 - 3029. [Abstract] [Full Text]

				X.-J. Zhou, L. B. Sheiner, R. T. D'Aquila, M. D. Hughes, M. S. Hirsch, M. A. Fischl, V. A. Johnson, M. Myers, J.-P. Sommadossi, and The National Institute of Allergy and Infectious D Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients Antimicrob. Agents Chemother., January 1, 1999; 43(1): 121 - 128. [Abstract] [Full Text]

				J. M. Adams, M. J. Shelton, R. G. Hewitt, T. H. Grasela, M. DeRemer, and G. D. Morse Relationship between Didanosine Exposure and Surrogate Marker Response in Human Immunodeficiency Virus-Infected Outpatients Antimicrob. Agents Chemother., April 1, 1998; 42(4): 821 - 826. [Abstract] [Full Text]